Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

740

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2011

Study Completion Date

May 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

Tamoxifen

20 mg po daily x 5 years

PROCEDURE

Surgery: Oophorectomy

Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)

Trial Locations (9)

Unknown

National Institute of Oncology, Rabat

Vicente Soto Memorial Medical Center, Cebu

East Avenue Medical Center, Manila

Philippine General Hospital, Manila

Rizal, Manila

Santo Toma Hospital, Manila

Danang General, Da Nang

Hospital K, National Cancer Institute, Hanoi

Hue Central, Huế

All Listed Sponsors
lead

International Breast Cancer Research Foundation

OTHER

NCT00201851 - Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer | Biotech Hunter | Biotech Hunter